Arrivo BioVentures’ RABI-767 Receives the US FDA’s Fast Track Designation for Treating Acute Pancreatitis
Shots:
- Panafina (Arrivo’s subsidiary) has reported the US FDA’s fast track designation granted to RABI-767 for treating severe acute pancreatitis
- The P-IIa study is investigating the safety & efficacy of a single dose of RABI-767 + SoC (delivered using endoscopic ultrasound-guided peripancreatic injection) vs SoC alone among patients at risk for severe acute pancreatitis
- RABI-767, a small molecule lipase inhibitor, stops the highly toxic cascade of fat necrosis that is responsible for tissue injury, systemic toxicity, organ failure and mortality in severe acute pancreatitis
Ref: Arrivo BioVentures | Image: Arrivo BioVentures
Related News:- AskBio’s (Bayer's Subsidiary) AB-1005 Gains the US FDA’s Fast Track and MHRA’s Innovation Passport Designations for Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
